Meeting
2019 ASCO Annual Meeting
A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC).
Authors
Seth Andrew Wander
Massachusetts General Hospital Cancer Center, Boston, MA
Seth Andrew Wander , Mark Zangardi , Andrzej Niemierko , Avinash Kambadakone , Leslie SL Kim , Jing Xi , Apurva Kumari Pandey , Laura Spring , Casey Stein , Dejan Juric , Irene Kuter , Beverly Moy , Therese Marie Mulvey , Neelima Vidula , Steven J. Isakoff , Megan Yuen , Adam Brufsky , Cynthia X. Ma , Joyce O'Shaughnessy , Aditya Bardia
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Breast Cancer—Metastatic
Track
Breast Cancer
Sub Track
Hormone Receptor-Positive
Citation
J Clin Oncol 37, 2019 (suppl; abstr 1057)
DOI
10.1200/JCO.2019.37.15_suppl.1057
Abstract #
1057
Poster Bd #
138
Abstract Disclosures
Similar Posters
Poster
2020 ASCO Virtual Scientific Program
Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.
First Author: Matthew P. Goetz
Poster
2023 ASCO Annual Meeting
Comparative overall survival of patients in trials of CKD4/6 inhibitors in combination with endocrine therapy in advanced breast cancer.
First Author: Coralea Kappel
Poster
2023 ASCO Annual Meeting
Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors.
First Author: Jesús Fuentes Antrás
Poster
2021 ASCO Annual Meeting
Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.
First Author: Nusrat Jahan